GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Retained Earnings

Aadi Bioscience (FRA:3350) Retained Earnings : €-264.27 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Aadi Bioscience's retained earnings for the quarter that ended in Mar. 2024 was €-264.27 Mil.

Aadi Bioscience's quarterly retained earnings declined from Sep. 2023 (€-236.77 Mil) to Dec. 2023 (€-246.64 Mil) and declined from Dec. 2023 (€-246.64 Mil) to Mar. 2024 (€-264.27 Mil).

Aadi Bioscience's annual retained earnings declined from Dec. 2021 (€-126.28 Mil) to Dec. 2022 (€-191.82 Mil) and declined from Dec. 2022 (€-191.82 Mil) to Dec. 2023 (€-246.64 Mil).


Aadi Bioscience Retained Earnings Historical Data

The historical data trend for Aadi Bioscience's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Retained Earnings Chart

Aadi Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Retained Earnings
-26.79 -126.28 -191.82 -246.64

Aadi Bioscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -204.01 -218.19 -236.77 -246.64 -264.27

Aadi Bioscience Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Aadi Bioscience  (FRA:3350) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Aadi Bioscience (FRA:3350) Business Description

Traded in Other Exchanges
Address
17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines